ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 171

Disease Modifying Agents Combined with Isoniazid for Latent Tuberculosis in Patients with Rheumatic Diseases

Josiane Bourré-Tessier1, Mireia Ariño i Torregrosa2 and Denis Choquette3, 1Médecine, Institut de Rhumatologie de Montréal, Université de Montréal, Montréal, QC, Canada, 2Universitat de Valencia, Massanassa, Spain, 3Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: DMARDs and tuberculosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Infection-related Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Reactivation of latent tuberculosis (LTB) has been described with the use of anti-TNF for the treatment of rheumatic diseases. Combined treatment of isoniazid (INH) and DMARDs such as methotrexate (MTX) and sulfasalazine (SSZ) can potentially increase the risk of liver toxicity. The goal of this study was to investigate the risk of liver toxicity in rheumatic patients taking isoniazid (INH) and disease modifying agents (DMARDs) or biologics.

Methods: We reviewed the Institut de Rhumatologie de Montréal database (RhumaData®) for rheumatic patients with positive tuberculin skin test who took INH and at least one concomitant DMARD or biologic between August 2001 and April 2011. Liver function tests (LFT) were tested at baseline and during therapy.

Results: Of 922 patients screened with tuberculin skin test, 87 patients tested positive and received INH. During INH treatment, 75.9% were taking concomitant DMARDs (71.3% MTX, 19.5% hydroxychloroquine (HCQ), 5.7% SSZ, 3.4% leflunomide), 82.0% were taking concomitant biologics, and 46.0% were using NSAIDs on a regular basis.  Twenty-four percent had abnormal liver enzymes during INH therapy. Most of them were mild or transient, but 8% (7 patients) had significant abnormalities leading to INH discontinuation. Among these patients, mean (min, max) was 241 (52, 617) for AST and 262 (92, 669) for ALT. Concomitant medications taken by patients who stopped INH were: biologics (4 patients), MTX (1), biologic and MTX (1), biologic, leflunomide and HCQ (1).

Conclusion: The use of INH for LTB was generally well tolerated in patients with rheumatic diseases on a background regimen of DMARDs or biologics. However, the rate of significant abnormalities is our study is higher than the reported rates for INH hepatitis in the literature. There is no evident association between liver anomalies and specific combination with DMARDs.  Therefore, it is prudent to follow LFT closely on patients taking combination therapy.


Disclosure:

J. Bourré-Tessier,
None;

M. Ariño i Torregrosa,
None;

D. Choquette,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-modifying-agents-combined-with-isoniazid-for-latent-tuberculosis-in-patients-with-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology